Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Jun 06, 2023

Read More

Zai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting

Jun 01, 2023

Read More

Zai Lab Announces Participation in June Investor Conferences

May 25, 2023

Read More

Zai Lab Announces That Repotrectinib Granted Priority Review by China’s NMPA

May 18, 2023

Read More

Zai Lab Announces First Quarter 2023 Financial Results and Corporate Updates

May 09, 2023

Read More

Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology

Apr 27, 2023

Read More

Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 26, 2023

Read More

Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023

Apr 20, 2023

Read More